跳至主要内容
临床试验/NCT05885022
NCT05885022招募中不适用

Feasibility Clinical Evaluation of the Calibreye System

Myra Vision Inc.7 个研究点 分布在 3 个国家目标入组 60 人开始时间: 2023年5月31日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
60
试验地点
7
主要终点
Intraocular Pressure

研究概览

简要总结

To evaluate the safety and feasibility of the Calibreye System in patients with open angle glaucoma.

详细描述

This is a prospective, nonrandomized, open-label feasibility clinical trial, to evaluate the surgical procedure, safety and effectiveness of the Calibreye System in reducing intraocular pressure in subjects with open angle glaucoma.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Open angle, pseudoexfoliative or pigmentary glaucoma
  • IOP at preoperative visit of ≥ 18mmHg and ≤ 45mmHg
  • Visual field mean deviation score of -3dB or worse
  • Area of healthy, free and mobile conjunctiva in the target quadrant
  • Shaffer angle grade ≥ 3 in the target quadrant

排除标准

  • Angle closure glaucoma
  • Congenital, neovascular or other secondary glaucomas
  • Previous intraocular surgery (with the exception of laser trabeculoplasty or uncomplicated phacoemulsification with IOL occurring > 3 months prior to the preoperative visit)
  • Previous glaucoma shunt/valve in the target quadrant
  • Clinically significant inflammation or infection in the study eye within 30 days prior to the preoperative visit
  • History of corneal surgery, corneal opacities or corneal disease
  • Active diabetic retinopathy

结局指标

主要结局

Intraocular Pressure

时间窗: 12 Months

Percent change in IOP from baseline to the 12-month visit

Adverse Events

时间窗: 12 Months

Number and percentage of subjects having any adverse event

次要结局

  • Glaucoma Medication Usage(12 Months)

研究者

发起方
Myra Vision Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验